Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F25%3A10487954" target="_blank" >RIV/00064203:_____/25:10487954 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/25:10487954

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=raDP.In0pk" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=raDP.In0pk</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2024.286082" target="_blank" >10.3324/haematol.2024.286082</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study

Popis výsledku v původním jazyce

This is a retrospective study of pseudonymized clinical data reported to the EuropeanSociety for Blood and Marrow Transplantation (EBMT) registry. The study was approved bythe Pediatric Diseases Working Party (PDWP) of the EBMT institutional review board andconducted in accordance with the Declaration of Helsinki. Children (age &lt;18y) with acutemyeloid (AML) or lymphoblastic leukemia (ALL) receiving the first allogeneic HSCT between2005 and 2021 were included. All patients received a bone marrow or peripheral bloodtransplant from an HLA-matched unrelated donor (10/10 at loci A, B, C, DRB1 and DQB1 inhigh resolution) uniformly. Transplant procedures using in vivo T-cell depletion (ATG oralemtuzumab) were included. Cord-blood transplantation, transplant procedures involving exvivo T-cell depletion or PTCy were excluded. The primary objective was to assess the impactof donor CMV serology on overall survival (OS) in pediatric HSCT recipients with AML orALL. The secondary objectives were the comparison of leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse incidence (RI), incidence of both acute graft versus hostdisease (aGvHD) and chronic GvHD (cGvHD), and GvHD-free/relapse-free survival (GRFS)between the seropositive (D+) and seronegative (D-) donor groups.

Název v anglickém jazyce

Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study

Popis výsledku anglicky

This is a retrospective study of pseudonymized clinical data reported to the EuropeanSociety for Blood and Marrow Transplantation (EBMT) registry. The study was approved bythe Pediatric Diseases Working Party (PDWP) of the EBMT institutional review board andconducted in accordance with the Declaration of Helsinki. Children (age &lt;18y) with acutemyeloid (AML) or lymphoblastic leukemia (ALL) receiving the first allogeneic HSCT between2005 and 2021 were included. All patients received a bone marrow or peripheral bloodtransplant from an HLA-matched unrelated donor (10/10 at loci A, B, C, DRB1 and DQB1 inhigh resolution) uniformly. Transplant procedures using in vivo T-cell depletion (ATG oralemtuzumab) were included. Cord-blood transplantation, transplant procedures involving exvivo T-cell depletion or PTCy were excluded. The primary objective was to assess the impactof donor CMV serology on overall survival (OS) in pediatric HSCT recipients with AML orALL. The secondary objectives were the comparison of leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse incidence (RI), incidence of both acute graft versus hostdisease (aGvHD) and chronic GvHD (cGvHD), and GvHD-free/relapse-free survival (GRFS)between the seropositive (D+) and seronegative (D-) donor groups.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

1592-8721

Svazek periodika

110

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

5

Strana od-do

985-989

Kód UT WoS článku

001495075900017

EID výsledku v databázi Scopus

2-s2.0-105001675505